Sardine-Enriched Diet Could Lessen Likelihood of Developing Diabetes

Consuming a sardine-enriched diet may prevent the development of type 2 diabetes, according to a study recently published in Clinical Nutrition.

Researchers led by Diana A. Diaz-Rizzolo, PhD, of the Open University of Catalonia in Barcelona, Spain, point out that consuming fish could play a role in preventing diabetes, but the specific types of fish that offer that protection haven’t been identified. Sardines are rich in omega-3 and taurine, which the authors write could delay the development of type 2 diabetes. The authors hypothesized that the consuming sardines twice a week for one year could reduce the risk of developing type 2 diabetes in a population with prediabetes and old age.

Consuming sardines twice a week for one year could reduce the risk of developing type 2 diabetes in a population with prediabetes and old age.

The researchers recruited 152 participants with fasting glucose between 100-124 mg/dL and aged ≥65 and randomly distributed these patients into two groups: the sardine group and the control group. “Both groups received same [type 2 diabetes]-prevention nutritional during a year but only [the sardine group] had to add 200 g of sardine per week,” the authors write. “All variables were collected before to start and at the end of the diet.”

Participants in the sardine group showed an increase in HDL-cholesterol and adiponectin and a decrease in triglycerides and blood pressure, as well as a lower HOMA-IR. Based on these results, the authors conclude that a year of consuming a sardine-rich diet has a greater protective effect against developing type 2 diabetes and cardiovascular events.

 

You may also like

  • Should  SGLT2 Inhibitors Be Stopped Before Emergency Surgery?

    A new study entitled “Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users” published in JAMA Surgery calls into question the current guidelines advising doctors to pause a widely used class of diabetes drugs—sodium-glucose cotransporter 2 inhibitors (SGLT2i) — before surgery. The findings suggest the risk of developing postoperative euglycemic ketoacidosis (eKA), a serious and potentially…

  • At Arm’s Length: A Look at a New Mealtime, Injection-Free Insulin Patch

    Priyanka Majety, MD, discusses a new, FDA-approved wearable insulin-delivery patch that could potentially improve patients’ insulin adherence as well as their quality of life. Last summer, a wearable patch designed for mealtime insulin delivery (in lieu of traditional injections) received clearance from the U.S. Food and Drug Administration, extending the patch’s wear time from three…